Provectus Biopharmaceuticals Issues Message to Stockholders

A new message to stockholders from Provectus Biopharmacuticals (NYSEMKT:PVCT) gives an overview of 2015, and a look ahead to 2016.
According to the message:

With the opening of our phase 3 trial for PV-10 as a treatment for Stage III melanoma, commencement of our phase 1b/2 trial combining PV-10 with Merck’s Keytruda® as a treatment for Stage IV melanoma, progress being made to bring PV-10 to Chinese and other markets as a treatment for cancers of the liver, and completion of enrollment in our mechanism of action studies for PV-10 and PH-10, 2015 has already been extremely important to Provectus. We believe that the remainder of 2015 and early 2016 will be highly significant in our corporate history, and this is, therefore, an opportune time both to review the recent past and to look ahead to what the balance of the year holds for us.
In our most recent quarterly investor conference call, we laid out the five clinical and business value proposition pillars of PV-10 and PH-10, as well as our three key focus areas. As we progress, these will continue to be useful guideposts to our overall business strategy and implementation of our plans.
The first pillar is our intellectual property. We hold a number of patents covering both PV-10 and PH-10 in the U.S. and overseas. Such patents form the basis for success for any biotech firm, and we believe the patents awarded, allowances received and future patents for which we will apply will allow us to maximize the financial rewards that will accrue to us if and when our investigational drugs receive regulatory approval. Our patents extend back to 2002, and recently we jointly received with Pfizer U.S. Patent number 9,107,887. We believe this patent protects the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination with systemic inhibitors of immune system down-regulation, such as anti-CTLA-4, PD-1 and PD-L1 antibodies, along with enhancers of immune system up-regulation, such as IL-2 and interferon-gamma. Pre-clinical testing of PV-10 used in combination with these important classes of drugs demonstrated potential importance for treatment of advanced cancers.

Click here to read the full message from Provectus.